Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial

Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

StandardStandard

Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial. / Sivaprasad, S; Hykin, P; Prevost, A.T. et al.
NIHR, 2018.

Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

HarvardHarvard

Sivaprasad, S, Hykin, P, Prevost, AT, Vasconcelos, J, Riddell, A, Ramu, J, Murphy, C, Kelly, J, Edwards, R, Yeo, ST, Bainbridge, J, Hopkins, D & White-Alao, B 2018, Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial. NIHR.

APA

Sivaprasad, S., Hykin, P., Prevost, A. T., Vasconcelos, J., Riddell, A., Ramu, J., Murphy, C., Kelly, J., Edwards, R., Yeo, S. T., Bainbridge, J., Hopkins, D., & White-Alao, B. (2018). Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial. NIHR.

CBE

Sivaprasad S, Hykin P, Prevost AT, Vasconcelos J, Riddell A, Ramu J, Murphy C, Kelly J, Edwards R, Yeo ST, et al. 2018. Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial. NIHR.

MLA

Sivaprasad, S et al. Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial NIHR. 2018.

VancouverVancouver

Sivaprasad S, Hykin P, Prevost AT, Vasconcelos J, Riddell A, Ramu J et al. Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY): a noninferiority randomised trial. NIHR, 2018.

Author

Sivaprasad, S ; Hykin, P ; Prevost, A.T. et al. / Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY) : a noninferiority randomised trial. NIHR, 2018.

RIS

TY - BOOK

T1 - Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY)

T2 - a noninferiority randomised trial

AU - Sivaprasad, S

AU - Hykin, P

AU - Prevost, A.T.

AU - Vasconcelos, J

AU - Riddell, A

AU - Ramu, J

AU - Murphy, C

AU - Kelly, J

AU - Edwards, Rhiannon

AU - Yeo, Seow Tien

AU - Bainbridge, J

AU - Hopkins, D

AU - White-Alao, B

PY - 2018/1

Y1 - 2018/1

N2 - NIHR Efficacy and Mechanistic Evaluation (EME) Programme Report

AB - NIHR Efficacy and Mechanistic Evaluation (EME) Programme Report

M3 - Commissioned report

BT - Clinical Efficacy, Cost-effectiveness and Mechanistic Evaluation of aflibercept for Proliferative Diabetic Retinopathy (acronym CLARITY)

PB - NIHR

ER -